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Abstract
Allodynia, hyperalgesia and spontaneous pain are cardinal sensory signs of neuropathic
pain. Clinically, many neuropathic pain patients experience affective-motivational state
changes, including reduced familial and social interactions, decreased motivation, anhedo-
nia and depression which are severely debilitating. In earlier studies we have shown that
sciatic nerve chronic constriction injury (CCI) disrupts social interactions, sleep-wake-cycle
and endocrine function in one third of rats, a subgroup reliably identified six days after injury.
CCI consistently produces allodynia and hyperalgesia, the intensity of which was unrelated
either to the altered social interactions, sleep-wake-cycle or endocrine changes. This de-
coupling of the sensory consequences of nerve injury from the affective-motivational
changes is reported in both animal experiments and human clinical data. The sensory
changes triggered by CCI are mediated primarily by functional changes in the lumbar dorsal
horn, however, whether lumbar spinal changes may drive different affective-motivational
states has never been considered. In these studies, we used microarrays to identify the
unique transcriptomes of rats with altered social behaviours following sciatic CCI to deter-
mine whether specific patterns of lumbar spinal adaptations characterised this subgroup.
Rats underwent CCI and on the basis of reductions in dominance behaviour in resident-in-
truder social interactions were categorised as having Pain & Disability, Pain & Transient Dis-
ability or Pain alone. We examined the lumbar spinal transcriptomes two and six days after
CCI. Fifty-four ‘disability-specific’ genes were identified. Sixty-five percent were unique to
Pain & Disability rats, two-thirds of which were associated with neurotransmission, inflam-
mation and/or cellular stress. In contrast, 40% of genes differentially regulated in rats with-
out disabilities were involved with more general homeostatic processes (cellular structure,
transcription or translation). We suggest that these patterns of gene expression lead to ei-
ther the expression of disability, or to resilience and recovery, by modifying local spinal cir-
cuitry at the origin of ascending supraspinal pathways.
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Introduction
The affective-motivational consequences of nerve injury have become an emerging focus of rat
models of neuropathic pain. The negative affective consequences of the spared nerve injury
(SNI) [1]; spinal nerve ligation (SNL) [2]; and chronic constriction injury of sciatic nerve
(CCI) [3] models of neuropathy, have been assessed using conditioned place aversion / place
escape avoidance paradigms, and inferred from analgesic conditioned place preference [4–8].
These studies provide evidence for the immediate (day-3 post injury) and persisting (4 weeks
post-injury) perception of unpleasantness of neuropathic injury [4, 5, 8], and for its reversal by:
(i) analgesics acting at spinal alpha-2 adrenoreceptors or, N-type calcium channels and; (ii) in-
hibition of supra-spinal facilitatory pathways [6, 7].
In tests, which evaluate anxiety-like and depression-like behaviours, SNL appears to have
little effect [9], whereas, CCI triggers clear anxiety and depression-like behaviours in all injured
rats [10–16]. Further in the SNI model, rats show anxiety-like behaviours [17, 18]. Anxiety and
depression-like behaviours have been first reported at 7 days following injury and persist for
up to 6 months after injury.
Attempts to evaluate the impact of nerve injury on hedonic processes have resulted in equiv-
ocal findings. The continuous monitoring of sucrose (15%) preference in individual rats reveals
an anhedonic impact of CCI from day 7 post-injury onwards [19]. In contrast, episodic sucrose
preference testing revealed no effect (2 consecutive nights, week 3 post-injury), similarly, the
ingestion of sweet cereal rewards at two weeks post-injury was not impacted by CCI [5, 15].
Sleep-wake cycles are also disrupted by nerve injury (although see [20]). SNI increased the
frequency of episodes of wakefulness and slow-wave sleep [21]. CCI also disrupts the sleep-
wake cycle, however, the precise characteristics of the disruptions appear to depend on the
strain of the rat, the diurnal phase of measurement, the housing conditions, whether one or
two nerves are ligated, as well as the post-injury time of recordings [22–24].
On balance, of the studies investigating affective-motivational changes following nerve inju-
ry, the CCI model has been the most widely investigated and has revealed the most robust find-
ings. Specifically, by the first week following injury, CCI triggers a state of unpleasantness,
associated with anxiety and depression-like behaviours, coupled to varying degrees of anhedo-
nia and sleep disturbance.
Work from our laboratory has focused on the CCI model and has shown changes in social
interactions [25–30], sleep-wake-cycle [27] and endocrine function (hypothalamo-pituitary
adrenal & thyroid) [31, 32] immediately after the injury in half of CCI rats. We have shown
that these changes persist for at least sixteen days in a subgroup of approximately one third of
CCI rats and that this subgroup of rats can be reliably identified after only six days of observa-
tion [27]. The subgroup was originally identified from observations in a large cohort of CCI
rats (n = 46), which leads us to suggest that in studies with smaller cohorts, this subpopulation
may simply be regarded as outliers. CCI consistently produced thermal and mechanical, allo-
dynia and hyperalgesia, the intensity of which was unrelated to the presence of altered changes
in social interactions [25–30], sleep-wake-cycle [27] and endocrine function [31, 32]. A decou-
pling of the sensory consequences of nerve injury (allodynia and hyperalgesia) from the affec-
tive-motivational changes triggered by nerve injury have also been reported in the place escape
avoidance paradigm following lesions or direct stimulation of the anterior cingulate cortex [33,
34]; conditioned place aversion following low dose morphine administration [8] and; condi-
tioned place preference following either intra-thecal adenosine injections or lesions of the ante-
rior cingulate [6, 35]. In humans a similar dissociation of sensation and affective-motivational
state is illustrated by: (i) ‘non-patients with chronic pain’, individuals with chronic pain who
do not seek medical treatment, these people are often missing in clinical reports, although have
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been used as controls for clinical chronic pain patients in some studies [36–39] and; (ii) the
poor concordance of pain intensity with disruption of quality of life [40–44].
This decoupling of the sensory versus affective-motivational consequences of nerve injury
described in rats and humans is broadly accepted to reflect that each are represented at an-
atomically distinct supra-spinal sites. Furthermore, these observations suggest that affective-
motivational state changes are also driven, by some, but not all elements of the spinal circuits
that trigger sensory changes [6, 45].
Neural circuits in the sciatic nerve recipient dorsal horn of L4 to L6 lumbar spinal segments
primarily mediate the sensory changes triggered by sciatic nerve CCI. Consequently, this re-
gion has been the focus of transcriptome studies whose aim has been to identify nerve injury-
evoked gene expression, which may lead to neuropathic pain [46–49]. The critical role of these
transcriptional changes in the spinal adaptations specific to either sensory or, affective-motiva-
tional changes cannot be determined in these studies. The fact that we can define subgroups of
rats either with, or without, altered social behaviours and sleep-wake cycles after CCI, does per-
mit the identification of specific transcriptional changes that may play important roles in the
expression of certain disrupted behaviours. In these studies, we used microarrays to identify
the unique transcriptomes of rats with altered social behaviours following sciatic CCI to deter-
mine whether specific patterns of spinal adaptations characterised this subgroup. We examined
the spinal transcriptomes two days and six days after CCI and in line with a recent meta-analy-
sis of microarray studies [49], our analysis focused on the key processes of; (i) neurotransmis-
sion, (ii) inflammation and/or cellular stress, (iii) cellular signalling; (iv) cellular structure; (v)
ionic balance and (vi) transcriptional and translational processes. Because our overall aim was
to describe the spinal adaptations specific to altered activity in spinal neurons that might drive
affective-motivational change, our first step was to interrogate the transcriptional changes in
the neurotransmission functional group using RT-PCR.
Methods
Animals
All experimental procedures were carried out in accordance with: the guidelines of the
NHMRC “Code for the Care and Use of Animals in Research in Australia”; the “Ethical Guide-
lines for Investigations of Experimental Pain in Conscious Animals” laid down by the Interna-
tional Association for the Study of Pain [50] and; the ARRIVE guidelines (https://www.nc3rs.
org.uk/arrive-guidelines). Furthermore, the University of Sydney Animal Care and Ethics
Committee approved all procedures (# 3920). All procedures were designed to minimise the in-
tensity and duration of animal suffering as well as animal numbers, within the context of ad-
dressing the experimental aims.
Experiments were performed on outbred, male Sprague-Dawley rats, (ARC, Australia)
weighing 250g-310g on the day of CCI. Male rats were selected to remove the need to control
for oestrus cycle related variation in spinal cord gene regulation. Rats were housed individually
in clear Perspex cages in an animal house maintained on a reversed 12/12 light/dark cycle with
lights on at 19–30h, with food and water available ad libitum. The behavioural analyses were
conducted during the dark phase of the circadian cycle. Room temperature was maintained at
22 (±1)°C.
‘Resident-intruder’ social interactions testing
Each ‘resident’ rat was habituated to its home-cage for a period of one-week, before the intro-
duction of a novel, sex, age and weight-matched conspecific of the same strain, (the ‘intruder’)
for six minutes every day (see [27] for complete details). Rats were allocated randomly to either
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the ‘resident’ or the ‘intruder’ groups. Briefly, resident-intruder social interactions (6 minutes)
were analysed for five days pre-CCI. The CCI surgery was performed on the day after social in-
teractions testing on day five. Post-CCI behavioural testing continued for either two days
(n = 27), or six days (n = 88).
Testing was performed at 09–30h each day 2 hours after lights off. Using an infrared camera
each rat was recorded for one minute prior to the introduction of the intruder, and then for six
minutes in the presence of the intruder. Resident rats never encountered the same intruder on
consecutive days, and never more than twice throughout testing.
Chronic constriction injury of the sciatic nerve
CCI was performed identical to that first described by Bennett and Xie [3]. Briefly, anaesthesia
was induced with 5% halothane in 100% O2 (Laser Animal Health, Australia), and maintained
via a custom made facemask (2% in 100% O2). The ability to control the depth of anesthesia
and the rapid trajectory of recovery were the reasons that halothane anesthesia was chosen.
The right sciatic nerve was exposed by blunt dissection through the biceps femoris and four
ligatures (chromic gut, 5.0, Ethicon, Somerville, NJ, USA) were loosely tied, 1mm apart, just
proximal to the trifurcation of the sciatic nerve. Constriction was minimal to cause “visible re-
tardation, but not arrest, of the epineural vasculature” as originally defined [3]. The incision
was sutured (Mersilk, 5.0, Ethicon) and iodine solution (Povidone-Iodine, Orion Laboratories
Pty. Ltd., Australia) and triple antibiotic powder (Tricin, Sigma) were applied topically. Each
rat was observed closely during its recovery period and during the 24h following its return to
the home-cage.
Behavioural analyses
The residents behaviour during the six minute test period was quantified within four mutually
exclusive categories:
• Dominance behaviour: standing on top of the supine intruder, back or lateral attack with
biting targeted at the neck or back of the intruder, and chasing the intruder.
• Social behaviour: investigation or sniffing of the intruder with particular focus on
anogenital region.
• Non-social behaviour: cage exploration and self-grooming.
• Submissive behaviour: defensive alerting/freezing, defensive sideway or supine posture
upon the approach of the intruder.
These categories were identical to those used previously by Monassi and colleagues, and are
based on earlier descriptions of Grant and Mackintosh [51].
Development of stable resident-intruder interactions requires prior intruder exposure there-
fore the behaviour of each resident on the post-CCI days was compared with its behaviour on
the 3 days immediately prior to CCI (i.e. pre-CCI days 3–5). Resident’s were then categorised
based upon changes in the duration of dominance behaviour post-CCI as follows; for rats tested
for six days post-CCI, we identified the three subgroups defined in our earlier studies: (i) Pain
alone: No change in the duration of dominance behaviour post-CCI, compared to pre-CCI. (ii)
Pain & Disability: A reduction of at least 30% in the duration of dominance behaviour on at least
5 out of 6 post-CCI days, compared to pre-CCI days. (iii) Pain & Transient Disability: An initial
transient reduction of at least 30% in the duration of dominance behaviour on the first 3–4 days
post-CCI, compared to pre-CCI, followed by a return to pre-CCI levels (days 4/5-6).
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PLOS ONE | DOI:10.1371/journal.pone.0124755 April 23, 2015 4 / 34
For rats tested for two days post CCI, only two subgroups were selected for analysis: (i) rats
that showed no change in the duration of dominance behaviour on post-CCI days 1 and 2,
which are predicted to become Pain alone; and (ii) rats that showed a greater than 30% de-
crease in dominance on each of post CCI days 1 and 2, which are predicted to be either Pain &
Disability or Pain & Transient Disability.
Mechanical and thermal threshold testing alters gene expression [52, 53] and because we
have previously reported that changes in allodynia, hyperalgesia and spontaneous pain behav-
iours occur in all sciatic nerve CCI animals [25, 27], it was not conducted on these rats.
Statistical analysis of behaviour
A two way between-groups ANOVA evaluated the effects of time and post-injury behavioural
group on dominant, social, non-social and submissive behaviours. Significant main effects
were probed further using Bonferroni post-hoc comparisons between each of the behavioural
groups. The results are presented as means (± SEM).
Sacrifice
Following ‘resident-intruder’ testing each animal was rapidly decapitated under CO2 narcosis.
The spinal cord was immediately exposed and whole spinal cord segments L4-L6 were isolated
and the dura and rootlets were removed, before being placed in 0.2ml ice cold TRI-reagent
(Sigma, Castle Hill, NSW, Australia). Whole spinal cords were analysed because by days 2 and
6 post-CCI, bilateral changes in spinal cord gene regulation have been reported in other studies
[54–57]. These spinal cord blocks were then stored at -80°C until processed further. In addi-
tion, twelve uninjured rats served as controls, six were used for microarray studies and six for
RT-PCR experiments.
Microarray studies
Day 2 post-CCI. two pooled samples of RNA, each containing spinal cords from three
rats from each of the Pain alone (day 2); Pain & Disability / Transient Disability (day 2) and
uninjured control groups were analysed (6 microarrays).
Day 6 post-CCI. On two independent occasions, pooled samples of RNA extracted from
spinal cords of three rats from the Pain alone (day 6); Pain & Disability (day 6); Pain & Tran-
sient Disability (day 6) and uninjured control groups respectively, were analysed (4 microarrays
per independent experiment).
Replicate pooled samples were chosen for analysis in this study to highlight genes most like-
ly to characterise rats with or without disabilities, an approach identical to that used in other
microarray studies [29, 46, 47]. Pooled samples also strengthen the analysis offered by the Affy-
metrix Microarray Analysis Suite (MAS) version 5.0.
Total RNA was extracted from the spinal cord samples using the manufacturer’s TRI-re-
agent protocol (chloroform-phenol method). Total RNA was then purified using the GenElute
mammalian Total RNA kit (Sigma). RNA was assayed at wavelengths of 260 nm, 280 nm and
320nm using a UV spectrophotometer (Biochrom Ltd, UK) to determine the RNA concentra-
tion and 260nm/280nm ratio. At this point 6.67μg of RNA from the three spinal cord samples
designated for each group were pooled together, giving a total of 20μg per group. Using 20 μg
of total RNA, double stranded cDNA was synthesised for each sample in a two-step reaction,
using a “SuperScript Double-Stranded cDNA Synthesis Kit” (Invitrogen, Mulgrave, VIC, Aus-
tralia). The cDNA was then purified using a phenol/chloroform extraction with Phase-lock
gels (Eppendorf, Wesseling-Berzdorf, Germany), and then resuspended in RNase free water.
This step was followed by in vitro transcription labelling with biotinylated-UTP and-CTP,
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performed according to the manufacturer's recommendations to produce cRNA (Enzo Diag-
nostics; Millenium Science, Mulgrave, VIC, Australia). The cRNA transcripts were then puri-
fied, using a GenElute mammalian Total RNA kit (Sigma) and then quantitated and assayed,
again using the UV spectrophotometer. The cRNA was fragmented and the suitability of the
samples for further analyses was confirmed using Affymetrix GeneChip Test3 arrays (low
background, good overall signal intensity and low 3’/5’ ratios of housekeeping genes). Affyme-
trix Test-3 chips showed that all samples met each of the criteria required for further analysis
using the Rat Neurobiology U34 GeneChip (RNU34). Each sample was subsequently hybri-
dised for 16 hours to the RNU34 microarray following the standard Affymetrix protocol. The
arrays were then washed and stained according to the Affymetrix fluidics station Mini_euk2v3
protocol, followed by scanning in a gene array scanner (Hewlett Packard Instruments, TX,
USA).
Microarray data analysis
Affymetrix Microarray Analysis Suite (MAS) version 5.0 was used to analyse the microarrays
using Wilcoxon signed-rank test to generate a statistically significant signal detection value and
then; (i) determine the presence, and quantify the level of expression, of transcripts within each
probe set and; (ii) calculate the magnitude and call the significance of the fold change. Genes of
interest were identified, using a custom designed analysis tool [58], which identified increased
(‘present’ call in sample) or decreased (‘present’ call in control) regulation from greater than,
or equal to, 1.3 fold compared to uninjured controls. On day 2 post-CCI, because all microar-
rays were run at the same time, four pairwise comparisons were possible between control and
behavioural groups, therefore only two identical ‘present’ calls were required for a gene of in-
terest to be identified. In contrast, because post-CCI day 6 comparisons were conducted on
two separate occasions, only two pairwise comparisons were made between control and beha-
vioural groups, therefore genes of interest were identified by two identical present calls. In ad-
dition, day 2 biological replicates were compared to each other to determine the degree of
technical and biological variation between the samples. Genes were subsequently categorised,
at each time point, as either (i) genes similarly regulated in all rats in response to nerve injury,
that is ‘injury-dependent’ genes, which may be involved in sensory-discriminative aspects of
pain, or (ii) genes uniquely regulated with respect to changes in social behaviours, that may be
important in driving complex behavioural change following nerve injury, that is ‘disability-
specific’ genes. It is important to note that, at day 2 post-CCI Pain & Disability and Pain &
Transient Disability rats cannot be distinguished from each other, and constitute the Pain &
Disability / Transient Disability (day 2) group. Genes were then grouped according to their pro-
tein-encoding function.
Real-time RT-PCR
Real-time RT-PCR was conducted for 17 selected genes from the neurotransmission group of
transcripts compared to ribosomal 18S as the housekeeping gene. The level of expression of ri-
bosomal 18S RNA remains stable under different experimental conditions or treatments, un-
like beta-actin, GAPDH and ubiquitin [59, 60]. Moreover, in our microarrays GAPDH was
differentially regulated, whilst 18S the housekeeping gene chosen for our PCR was confirmed
as having similar cycle threshold (Ct) values in each sample for the same amount of total RNA.
The primers used (listed in Table 1) were designed using the Primer Express/Gene Jockey
programs to determine the Tm and to check for secondary structures and primer dimers. Prim-
ers were designed so that, where possible, the amplicon would cross at least one exon/intron
boundary. All primers were custom made (Sigma Genosys, Castle Hill, NSW, Australia). In
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addition to analysis of the two replicates from the microarray experiments, RNA was extracted
from a further three rats for each behavioural group to provide n = 3 replicates from 9 individ-
ual rats. The uninjured control samples were run in triplicate and contained equal amounts of
RNA from six spinal cords pooled. Using 5μg total RNA for each sample, double stranded
cDNA was synthesised using SuperScript III (Invitrogen). The cDNA synthesised was sub-
jected to real-time PCR in the presence of SYBR Green (1:31250, Life Technologies) and for-
ward and reverse primers (see Table 1). Amplification was performed with an initial denature
at 95°C for 120s and then 30–40 cycles of 95°C for 30s (denaturing), 60–72°C for 30s (amplifi-
cation) and 72°C for 30s (fluorescence data acquisition). A melt and gel analysis on resulting
Table 1. Primer sequences for the genes examined using real time PCR.
Accession # Gene Primer Sequence Length
M11188 Ribosomal 18S Fwd 50 GCCGCTAGAGGTGAAATTCTTG 30 73 bp
Rev 50 GAAAACATTCTTGGCAAATGCTTT 30
AF020756 P2X2-3 Receptor Fwd 50 TGACAAGGGCAACATTGCAAGC 30 290 bp
Rev 50 TGGCAAACCTGAAGTTGTAGCCTG 30
AI229237 Opioid receptor-like Fwd 50 AAGCCCAGGTCTCTCTGACACAG 30 144 bp
Rev 50 TGTAACGCCCTTTCTATGGGTCAG 30
X55812 Cannabinoid receptor 1 Fwd 50 TACCTGATGTTCTGGATTGGGGTG 30 140 bp
Rev 50 GTGGATGATGATGCTCTTCTGGGTC 30
M93257 Catecholamine-O-methyltransferase Fwd 50 GCCAAAATAACAGCAGAGGCTCAG 30 198 bp
Rev 50 CCCTGGCTGTCTTGGAACTCAC 30
D00688 Monoamine oxidase A Fwd 50 AAGGGTGATTCGCCAGCCAG 30 195 bp
Rev 50 AATGGCTGGAACATCCTTGGACTC 30
AB016161 GABA-B1 Receptor Fwd 50 GGATGTGGAACCTTATTGTGCTCTTCA 30 178 bp
Rev 50 GGTGGTCTGTTGGATGGTAGCGAT 30
AA852004 Glutamine synthetase Fwd 50 GCCTTCTAATGGCTTCCCTGGAC 30 146 bp
Rev 50 ACCTCGGCATTTGTCCCTGTG 30
L08228 NMDA 1 subunit Fwd 50 GGTTCGGTATCAGGAATGCGACTC 30 166 bp
Rev 50 GCTTCCTACGGGCATCCTTGTG 30
U08259 NMDA-2C subunit Fwd 50 CACCATTGGGTCTGGCAAAGTC 30 191 bp
Rev 50 TTGCTGCTCATCACCTCATTCTTCTC 30
U08260 NMDA-2D subunit Fwd 50 GCTGTCTGGGTGATGATGTTCGTC 30 150 bp
Rev 50 TGGATTTCCCAATGGTGAAGGTAGAG 30
J03624 Galanin Fwd 50 GGGATGCCAACAAAGGAGAAGAGAG 30 134 bp
Rev 50 CAGTGGTAACTCCCTCTTGCCTGTG 30
M15191 Tachykinin Fwd 50 CAGAGGAAATCGGTGCCAACG 30 125 bp
Rev 50 TGGGTCTTCGGGCGATTCTC 30
M15580 Neuropeptide Y Fwd 50 CTGTGTGGACTGACCCTCGCTC 30 124 bp
Rev 50 GGTGATGAGATTGATGTAGTGTCGCAG 30
K02248 Somatostatin Fwd 50 GGACCCCAGACTCCGTCAGTTTC 30 127 bp
Rev 50 CCAGGGCATCGTTCTCTGTCTG 30
X53944 Dopamine 3 Receptor Fwd 50 CTTGGAGGTGACAGGT GGAGTCTG 30 165 bp
Rev 50 GGTGCCGTGCTGATAGTGAACTG 30
J05122 Peripheral Benzodiazepine Receptor Fwd 50 TGGTATGCTAGCTTGCAGAAACC 30 85 bp
Rev 50 CGAATACAGTGTGCCCCAGAT 30
M58587 Interleukin-6 receptor Fwd 50 GAATGGACTACCACGGGAAACACAC 30 202 bp
Rev 50 GTGCTGCTTGGATGCCACTCAC 30
doi:10.1371/journal.pone.0124755.t001
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PCR products determined the presence of a single specific product. All PCR products including
the housekeeping gene, 18S, were sequenced (n = 18), and confirmed the presence of a single
matching PCR product for each primer set (SUPAMAC, Sydney NSW, Australia). In addition,
no template controls (NTC) were run to determine the level of primer dimer formation and/or
contamination and negative reverse transcriptase samples were run with the GABBR1 primers
to confirm the absence of genomic contamination. The threshold cycle values were chosen in
the linear range, and relative expression changes normalised to the housekeeping gene. Ampli-
fication efficiency was determined using the Rotor Gene v6 software. The ratio of expression of
each gene in behavioural versus control samples was calculated using REST© (relative expres-
sion software tool) [61], which takes into account any variations in amplification efficiency.
Statistics were performed in REST using the Pair Wise Fixed Reallocation Randomisation Test.
Results
Resident-Intruder Social Interactions testing
Resident-intruder testing was carried out for 5 days prior to CCI during which time a stable
pattern of baseline behaviour was established. For the first minute after the introduction of the
intruder, the resident displayed predominantly social behaviours. Following this, the resident
began to display dominance behaviours towards the intruder, particularly, chasing, followed
often by lateral and back attacks with biting targeted at the neck or back of the intruder, who
characteristically responded with submissive behaviour. Towards the end of the 6-minute peri-
od the resident increasingly spent more time engaged in non-social and social behaviours. Sub-
missive behaviour was rarely displayed. On pre-CCI days 3–5 dominance behaviours
accounted for around 40% of the 6-minute test period.
Post CCI Day 2. Two days following nerve injury, in twelve of twenty-seven rats tested
(~44%) dominance behaviour was stable on days 1 and 2, these rats were classified as Pain
alone (day 2). A further eleven rats (~41%) showed significant reductions (of at least 30%) in
duration of dominance behaviours on both post-CCI days, these rats were classified as Pain &
Disability / Transient Disability (day 2). Four rats could not be classified in into either group.
Fig 1A and 1B summarises these behavioural outcomes for the 18 resident rats used in subse-
quent microarray and RT-PCR analyses at day 2. There was a significant reduction in domi-
nance behaviour in the Pain & Disability / Transient Disability (day 2) rats compared to Pain
alone (day 2) rats on both days after CCI (P<0.001), which was mostly accounted for by a sig-
nificant increase in non-social behaviour (P<0.001).
Post CCI Day 6. Six days after CCI, three distinct patterns of behaviour emerged. Firstly,
54 of the 88 (~61%) residents were classified in the Pain alone (day 6) group, maintaining dom-
inance behaviours towards the intruder after CCI. Twenty (~23%) of the residents were classi-
fied in the Pain & Disability (day 6) group, that is, they displayed a significant reduction (at
least 30%) in the duration of dominance behaviours on all of the post-CCI days. The remaining
14 residents (~16%) were classified in the Pain & Transient Disability (day 6) group, displaying
a transient (days 1–3 post-CCI) and significant reduction (~30%) in the duration of domi-
nance, after which behaviour returned to pre-injury levels on days 4–6 after CCI. Fig 1C and
1D show the behavioural outcomes, until 6 days after CCI, for the 27 residents used for subse-
quent gene expression assays. There was a significant reduction in dominance behaviour in the
Pain & Disability (day 6) rats compared to Pain alone (day 6) rats on all 6 post-CCI days
(P<0.001), which was mostly accounted for by a significant increase in non-social behaviour
(P<0.05-P<0.001). The Pain & Transient Disability (day 6) group had a significant reduction
in dominance behaviour, and an increase in non-social behaviour on days 1–3 after CCI com-
pared to Pain alone (day 6), but their behaviour returned to normal by days 5 and 6 after CCI.
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Microarray data
Changes in gene expression in L4-L6 spinal cord segments of nerve-injured, behaviourally cate-
gorised rats were detected using microarrays at two time points. Two days after CCI the num-
ber of probes sets present on the microarrays were 479 in uninjured controls; 486 in Pain alone
Fig 1. Resident-intruder social interactions testing following chronic constriction injury (CCI) of the sciatic nerve in disability categorised rats.
(A&B) Line graphs showing mean (± s.e.m.) duration of dominance and non-social behaviours up to 2 days after CCI, for Pain & Disability (n = 9) and Pain alone
(n = 9) rats. (C&D) Line graphs showing mean (± s.e.m.) duration of dominance and non-social behaviours up to 6 days after CCI, for Pain & Disability (n = 9),
Pain & Transient Disability (n = 9) and Pain alone (n = 9) rats. These graphs show pooled behavioural data for all animals used in gene expression studies. Using
a two-way ANOVA with a Bonferroni’s post-hoc test; * (P<0.05), ** (P<0.01) and *** (P<0.001) indicate a significant difference between Pain & Disability and
Pain alone rats, # (P<0.05) and ### (P<0.001) indicate a significant difference between Pain & Transient Disability and Pain alone rats, ^^^ (P<0.001) indicates a
significant difference between Pain & Disability and Pain & Transient Disability rats.
doi:10.1371/journal.pone.0124755.g001
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Table 2. A summary of all of the genes up- or down-regulated in the lumbar spinal cord of rats 2 days
after CCI determined by MAS v5.0. ALL indicates ‘injury-related’ genes, with regulation occuring in all rats
following CCI.
Gene (Symbol) Direction Animal Group
§Benzodiazepine peripheral receptor (BZRP) UP ALL
#Eukaryotic translation elongation factor 2 (EEF2) UP ALL
§Glial ﬁbrillary acidic protein (GFAP) UP ALL
Glutamine synthetase (GLUL) UP ALL
Mitogen activated protein kinase kinase 2 (MKK2) UP ALL
§Metallothionein 2A (MT2A) UP ALL
#Myelin protein zero (MPZ) UP ALL
SNAP-25A UP ALL
Agrin (AGRIN) DOWN ALL
§Catecholamine-O-methyltransferase (COMT) DOWN ALL
Cyclin L (CCLN1) DOWN ALL
Ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) DOWN ALL
#Myelin-associated glycoprotein (MAG) DOWN ALL
Opioid-like receptor 1 (OPRL1) DOWN ALL
§Potassium voltage gated channel, Shal-related, member 2 (KCND2) DOWN ALL
‡Complement component 3 (C3) UP P&D+TD
Solute carrier family 18, member 3 (SLC18A3) UP P&D+TD
‡Phosphoinositide 3-kinase p85 (PIK3R2) UP / DOWN P&D+TD / PA
Calcitonin-related polypeptide, beta (CALCB) DOWN P&D+TD
Calcium/calmodulin-dependent protein kinase I (CAMK1) DOWN P&D+TD
Glutamate receptor, AMPA, alpha 2 (GRIA2) DOWN P&D+TD
Neuropeptide Y (NPY) DOWN P&D+TD
†Prostaglandin F receptor (PTGRF) DOWN P&D+TD
Tachykinin (TAC1) DOWN P&D+TD
Somatostatin (SST) DOWN P&D+TD
α-Synuclein (SNCA) DOWN P&D+TD
Glutathione-S-transferase, alpha (GST) UP PA
‡Metallothionein 1A (MT1A) UP PA
Monoamine oxidase B (MAOB) UP PA
Nestin (NES) UP PA
‡Sodium channel, type VI, alpha polypeptide (SCN6A) UP PA
‡Vimentin UP PA
‡Voltage-dependent anion channel 1 (VDAC1) UP PA
Glycine receptor, alpha 1 (GLRA1) DOWN PA
‡Potassium channel, Shaw-related subfamily, member 1 (KCNC1) DOWN PA
†SRY-box containing gene 10 (SOX10) DOWN PA
Whilst, ‘disability-related’ genes, are denoted either, P&D+TD, if they are unique to Pain and Disability/
Transient Disability rats, or PA, if they are unique to Pain alone rats (i.e. non-disabled rats). Symbols denote
genes regulated at both 2 and 6 days, speciﬁcally:
§ persistent regulation in all CCI rats;
† persistent regulation in unique to Disability;
‡ delayed regulation with respect to Disability;
# failure of counter regulation to occur in rats with Pain and Disability.
doi:10.1371/journal.pone.0124755.t002
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Table 3. A summary of all of the genes up- or down-regulated in the lumbar spinal cord of rats 6 days
after CCI as determined by MAS v5.0.
Gene (Symbol) Direction Animal
Group
§Benzodiazepine peripheral receptor (BZRP) UP ALL
Calpain, small subunit 1 (CAPNS1) UP ALL
Chemokine (C-C motif) ligand 2 (CCL2) UP ALL
‡Complement component 3 (C3) UP ALL
Dopamine receptor 3 (DRD3) UP ALL
§Metallothionein 2A (MT2A) UP ALL
Gamma-aminobutyric acid B receptor, 1 (GABBR1) UP ALL
§Glial ﬁbrillary acidic protein (GFAP) UP ALL
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) UP ALL
Interleukin 18 (IL-18) UP ALL
Interleukin 6 receptor (IL-6R) UP ALL
Macrophage migration inhibitory factor (MIF) UP ALL
Myelin basic protein (MBP) UP ALL
§Catecholamine-O-methyltransferase (COMT) DOWN ALL
Glutamate receptor, ionotropic, kainate 4 (GRIK4) DOWN ALL
Glutamate receptor, N-methyl D-aspartate 2C (GRIN2C) DOWN ALL
Heat shock 27kD protein 1 (HSPB1) DOWN ALL
‡Phosphoinositide 3-kinase p85 (PIK3R2) DOWN ALL
§Potassium voltage gated channel, Shal-related family, member 2 (KCND2) DOWN ALL
Rattus norvegicus mRNA for tubulin (TUBG1) DOWN ALL
Solute carrier family 24, member 2 (SLC24A2) DOWN ALL
Apurinic/apyrimidinic endonuclease 1 (APE1) UP P&D
Calmodulin III (CAMIII) UP P&D
Calpain 1 (CAPN1) UP P&D
Cannabinoid receptor 1 (CNR1) UP P&D
Ciliary neurotropic factor (CNTF) UP P&D
G protein, beta polypeptide 2-like 1 (GNBL1) UP P&D
Galanin (GAL) UP P&D
Heat shock 10 kD protein 1 (HSP10) UP P&D
Heme oxygenase (HO) UP P&D
‡Metallothionein 1A (MT1A) UP P&D
Monoamine oxidase A (MAOA) UP P&D
Neuronal activity-regulated pentraxin (NARP) UP P&D
P2X, ligand-gated ion channel, 2 (P2RX2) UP P&D
†Prostaglandin F receptor (PTGRF) UP P&D
Proteasome subunit, alpha type 3 (PSMA3) UP P&D
RAB28, member RAS oncogene family (RAB28) UP P&D
Ras-related rab1B protein (RAB1B) UP P&D
Solute carrier family 1, member 2 (SLC1A2) UP P&D
Superoxide dismutase 1, soluble (SOD1) UP P&D
Superoxide dismutase 2, mitochondrial (SOD2) UP P&D
SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily b, member 1 (SMARCB1)
UP P&D
‡Vimentin (VIM) UP P&D
‡Voltage-dependent anion channel 1 (VDAC1) UP P&D
(Continued)
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(day 2); and 477 in Pain & Disability / Transient Disability (day 2) groups. Whilst for 6 days
after CCI the number of probe sets was, 582 for uninjured controls; 514 in Pain alone (day 6),
586 in Pain & Disability (day 6) and 558 in Pain & Transient Disability (day 6). The number of
differentially regulated probe sets, did not differ greatly between uninjured controls and the
behaviourally categorised rats at either time-point. Variation in the number of genes differen-
tially regulated between replicates at day 2 and at day 6 post-CCI was small and within levels
(<2%) considered acceptable using this technology [62].
Gene expression in the lumbar spinal cord unique to day 2
Two days after CCI a total of 36 genes were identified to have a change in their expression
greater than 1.3-fold, with 17 genes up-regulated and 18 genes down-regulated and one regu-
lated both up and down depending on the behavioural grouping, compared to uninjured con-
trol lumbar spinal cord (see Table 2). Of these 36 genes, 15 were common to both behavioural
groups (Pain alone (day 2) and Pain & Disability/Transient Disability (day 2)), which we have
termed ‘injury-dependent genes’. Eight of the genes were up-regulated and 7 down-regulated
(Table 2). Whilst, 21 genes were identified to be ‘disability-specific genes’, that is they were spe-
cifically regulated greater than 1.3-fold in one of the behavioural groups. Eleven of these were
Table 3. (Continued)
Gene (Symbol) Direction Animal
Group
#Myelin protein zero (MPZ) UP /
DOWN
P&D / PA
+TD
‡Sodium channel, type VI, alpha polypeptide (SCN6A) UP /
DOWN
P&D / PA
+TD
ATPase, Ca++ transporting, ubiquitous (ATP2A3) DOWN P&D
Glutamate receptor, N-methyl D-aspartate 1 (GRIN1) DOWN P&D
Glutamate receptor, N-methyl D-aspartate 2D (GRIN2D) DOWN P&D
Glycogen synthase kinase 3 beta (GSK3B) DOWN P&D
Neural cell adhesion molecule L1 (L1CAM) DOWN P&D
p38 mitogen activated protein kinase (MAPK14) DOWN P&D
‡Potassium channel, Shaw-related subfamily, member 1 (KCNC1) DOWN P&D
Early growth response 1 (EGR1) UP PA+TD
Forkhead box M1 (FOXM1) UP PA+TD
Mitogen-activated protein kinase kinase 1 (MAP2K1) UP PA+TD
#Myelin-associated glycoprotein (MAG) UP PA+TD
ATPase, Na+K+ transporting, alpha 1 polypeptide (ATP1A1) DOWN PA+TD
ATP-binding cassette, sub-family B (MDR/TAP), member 6 (TAP1) DOWN PA+TD
#Eukaryotic translation elongation factor 2 (EEF2) DOWN PA+TD
†SRY-box containing gene 10 (SOX10) DOWN PA+TD
ALL indicates ‘injury-related’ genes, with regulation occuring in all rats following CCI. Whilst, ‘disability-
related’ genes, are denoted either, P&D, if they are unique to Pain and Disability rats, or PA+TD, if they are
unique to Pain alone and Pain and Transient Disaility rats (i.e. non-disabled cohort). Symbols denote genes
regulated at both 2 and 6 days, speciﬁcally:
§ persistent regulation in all CCI rats;
† persistent regulation in unique to Disability;
‡ delayed regulation with respect to Disability;
# failure of counter regulation to occur in rats with Pain and Disability.
doi:10.1371/journal.pone.0124755.t003
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selectively regulated in Pain & Disability/Transient Disability (day 2) rats (3 up- and 8 down-
regulated, Table 2), whilst altered regulation of 11 genes was restricted to Pain alone rats (7
up- and 4 down-regulated, of which phosphoinositide 3-kinase p85 (PIK3R2) was also up-reg-
ulated in Pain & Disability/Transient Disability (day 2)).
Gene Expression in the Lumbar Spinal Cord Unique to Day 6
Six days after CCI a total of 61 ‘injury-dependent genes’ were identified to have a significant
change in their expression of greater than 1.3-fold compared to uninjured control lumbar spi-
nal cord (see Table 3). Forty-two genes were up-regulated and 21 genes down-regulated (in-
cluding 2 genes that were both up- and down-regulated but in different behavioural groups).
Of these 61 genes, 21 ‘injury-dependent genes’ were identified to be specifically regulated in
rats from all three behavioural groups compared to control animals, 13 being up-regulated and
8 being down-regulated (see Table 3).
Six days after CCI it is possible to identify a sub-population of rats that have ongoing beha-
vioural disabilities (i.e. Pain & Disability (day 6) group), mimicking the presentation of human
neuropathic pain patients. Therefore the gene expression patterns unique to this group may be
particularly important to the pathophysiology of clinical neuropathic pain. Indeed, 32 ‘disabili-
ty-specific genes’, were identified as being selectively regulated in only Pain & Disability (day
6) rats compared to uninjured controls. Twenty-five of these were up-regulated and 7 down-
regulated (Table 3). A further 10 genes were selectively regulated in rats without persistent dis-
ability (i.e. Pain alone (day 6) and Pain & Transient Disability (day 6)) 6 days after CCI. Four
genes were up-regulated and 6 genes were down-regulated, of which 2 were also up-regulated
in Pain & Disability (day 6) rats (Table 3). Therefore, a total of 40 ‘disability-specific’ genes
were identified in the lumbar spinal cord 6 days after CCI.
Genes regulated at both day 2 and day 6
Of the 80 genes regulated at either day 2 or day 6 post-injury, seventeen genes were regulated
at both days 2 and 6. These genes fell into 4 distinct patterns; (i) persistent regulation common
to CCI, (ii) delayed gene regulation with respect to disability, (iii) persistent regulation unique
to disability and (iv) failure of counter-regulation to occur in animals with Pain & Disability
(Tables 2 and 3).
Five genes displayed persistent regulation common to CCI, the glial fibrillary acidic protein
(GFAP, up); metallothionein 2A (MT2A, up); peripheral benzodiazepine receptor (BZRP, up);
catecholamine-O-methyltransferase (COMT, down) and potassium channel shal-related mem-
ber 2 (KCND2, down) genes, were regulated in the same direction on both days common to
the CCI, that is they were regulated similarily in all animals at both day 2 and day 6 after CCI.
There were 7 genes which had delayed regulation with respect to the expression of disability
following CCI. In the lumbar spinal cord of rats with Pain & Disability (day 6) the genes for
vimentin (VIM), voltage dependent anion channel 1 (VDAC1), metallothionein-1A (MT1A),
and sodium channel type VI alpha (SCN6A), had up-regulation delayed until day 6 after CCI,
contrastingly animals with Pain alone (day 2) display a similar upregulation earlier at day 2. As
a result of the delayed up-regulation of SCN6A in Pain & Disability (day 6) rats, until day 6
after CCI, they differ from Pain alone (day 6) and Pain & Transient Disability (day 6) rats,
which by day 6 displayed a subsequent down-regulation. Conversely, potassium channel shaw-
related member 1 (KCNC1), had delayed down-regulation in the lumbar spinal cord of animals
with Pain & Disability (day 6) until day 6 after CCI. There was delayed up-regulation of com-
plement component 3 (C3) in rats with Pain alone and a delayed down-regulation of
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phosphoinositide 3-kinase p85 (PIK3R2) in Pain & Disability rats (which actually increased),
when changes in day 2 post-CCI rats were compared to rats at day 6 post-CCI.
Two changes in gene expression were found to occur exclusively in a single behavioural
group. SRY-box containing gene 10 (SOX10) was down-regulated at both day 2 and day 6 after
CCI in the spinal cord of rats without disability (Pain alone and Pain & Transient Disability
groups). Whilst the gene for prostaglandin F receptor (PTGRF) was selectively regulated in the
spinal cord of rats with Pain & Disability, initially being down-regulated 2 days after CCI, but
subsquently up-regulated by day 6.
Three genes, eukaryotic translation elongation factor 2 (EEF2, up), myelin protein zero
(MPZ, up) and myelin-associated glycoprotein (MAG, down), were regulated similarily in the
lumbar spinal cord of all rats 2 days after CCI, but subsequently at day 6 the direction of regula-
tion selectively changed in only rats without disability (Pain alone and Pain & Transient Dis-
ability groups). Thus, these genes can be considered ‘injury-dependent’ at day 2 and ‘disability-
specific’ at day 6.
The remaining 63 genes were regulated selectively in the lumbar spinal cord at only day 2 or
day 6 after CCI (see Tables 2 and 3). Nineteen of these changes in gene regulation were found
to occur at only day 2 following sciatic CCI, with 7 ‘injury-dependent’ genes and 12 ‘disability-
specific’ genes (8 genes regulated selectively in Pain & Disability / Transient Disability rats and
4 genes regulated in rats with Pain alone). At day 6 following CCI, 44 genes were specifically
regulated, 14 ‘injury-dependent’ genes, and 30 ‘disability-specific’ genes (25 genes selectively
regulated in Pain & Disability rats, and 5 genes regulated in rats with Pain alone and Pain &
Transient Disability).
To summarise, at both post injury days 2 and 6, eighty genes were regulated greater than
1.3-fold in the lumbar spinal cord (Tables 2 and 3). Of these genes, 26 were strictly ‘injury-de-
pendent’; 49 were strictly ‘disability-specific’; 3 genes were initially ‘injury- dependent’, chang-
ing to ‘disability-specific’ by day 6; whilst 2 genes were ‘disability-specific’ at day 2 changing to
‘injury-dependent’ by day 6. All genes were subsequently categorised according to the function
of the protein which they encoded; neurotransmission (n = 23, Fig 2), inflammation and/or
cellular stress (n = 22, Fig 3), cellular signalling (n = 11, Fig 4), cellular structure (n = 9, Fig 5),
ionic balance (n = 8, Fig 6) and transcriptional and translational processes (n = 7, Fig 7). Be-
cause our overall aim was to begin to describe the spinal adaptations specific to altered activity
in spinal neurons that might drive affective-motivational change, we proceeded to interrogate
the transcriptional changes in the neurotransmission functional group using RT-PCR.
Real-Time RT-PCR Data
RT-PCR was used to confirm the microarray results for 17 genes primarily from the neuro-
transmission functional group. These genes were chosen based on their significant changes in
gene expression, as well as having a functional role in neurotransmission in the nociceptive
pathways of the spinal cord. Of the 17 genes tested, 10 (59%) showed changes in expression
pattern consistent with the changes identified by microarray analysis. Overall 7 genes were
found to be ‘injury-dependent’ being modulated in all nerve injury rats and 4 genes were ‘dis-
ability-specific’ being selectively regulated in only Pain & Disability animals. Although, perfect
congruence was not expected due to the inherent differences in sensitivity and dynamic range
between the two techniques, overall, the 59% agreement is in the expected range, based on sim-
ilar studies [49, 63, 64].
When the genes examined by real time RT-PCR were sub-divided into functional categories,
changes in receptor genes showed a high degree of congruence. Changes in 8 out of 10 receptor
genes detected by real time RT-PCR (Fig 8A), were consistent with the microarray findings. Of
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these 8 genes, 5 were ‘injury-dependent’ showing altered expression patterns in all nerve in-
jured rats. Two of the ‘injury- dependent’ genes showed identical patterns to the microarray,
with BZRP up-regulated at both time points and opioid-like receptor 1 (OPRL1) down-regulat-
ed only at day 2. The other three ‘injury-dependent’ genes, the GABAB (GABBR1), interleukin-
6 (IL-6R) and dopamine 3 (DRD3) receptors, showed up-regulation at both days 2 and 6,
whereas the microarray results indicated an increase only at day 6. Three genes, were con-
firmed by real time RT-PCR to be ‘disability-specific’ as in the microarray, being selectively
regulated in only Pain & Disability (day 6) rats at day 6; these were, cannabinoid receptor 1
(CNR1,up), NMDA subunits NR1 (GRIN1, down) and NR2D (GRIN2D, down). NMDA re-
ceptor subunit NR2C (GRIN2C) was previously identified as an ‘injury-dependent’ gene in the
microarray, however PCR revealed it to be a ‘disability specific’ gene, as it was down-regulated
at day 6 in Pain & Disability (day 6) rats. Given the RT-PCR analysis included mRNA from ad-
ditional CCI rats, it likely reflects a more accurate picture of the regulation of this gene. The
only gene of the receptor class which no longer showed any significant change in expression in
the RT-PCR analysis, was P2RX2.
Consistent with microarray findings, neurotransmitter degradation enzymes, COMT and
glutamine synthase (GLUL), were confirmed as ‘injury-dependent’ genes by real time RT-PCR
in (Fig 8B). With that said, down-regulation of COMT, was only congruent at day 6, with no
change in gene expression at day 2 after nerve injury. Whilst the up-regulation of GLUL was
identified at both timepoints, in contrast to the up-regulation restricted to day 2 in the microar-
ray analysis. The up-regulation of monoamine oxidase A (MAOA) in the Pain & Disability
group was not detected by real time RT-PCR.
Four ‘disability-specific’ genes for neuropeptides identified in the microarrays were not con-
firmed in real time RT-PCR (Fig 8C).
Discussion
We identified using microarrays, a total of 80 genes that were specifically regulated in the lum-
bar spinal cord in response to CCI. At 2 and 6 days after injury, 26 genes were considered ‘inju-
ry-dependent’ showing altered expression in all rats, whilst there were 54 ‘disability-specific’
genes, regulated in one or more of the disability groups. Using real time-PCR, we confirmed
the expression pattern of 7 ‘injury-dependent’ genes and 3 ‘disability-specific’ genes from the
microarrays, plus discovered the NMDA NR2C gene having ‘disability-specific’ regulation.
These findings provide insight into the temporal and dynamic response of gene expression
with regards to the development of both sensory abnormalities and disabilities following nerve
injury. The significance of our discovery of ‘disability-specific’ genes is emphasized by the fact
that forty percent of the genes identified in our study have been previously identified as ‘pain
genes’ according to the pain gene database (22 genes) and nineteen of the genes have been
identified in a recent and comprehensive ‘pain gene’ meta-analysis [49, 65]. This is the first
suggestion however, of a role for these genes in the expression of disability in neuropathic
conditions.
Injury-dependent gene changes
Microarrays were used to detect spinal cord gene regulation common to CCI rats in the imme-
diate (day 2) and early (day 6) stages of injury. CCI triggers a cascade of neural and
Fig 2. Gene transcripts, which encode for proteins involved in neurotransmission, that are specifically regulated in the lumbar spinal cord after
CCI, as determined by microarray analysis. Changes in gene expression have been tested at both 2 and 6 days after CCI on pooled mRNA samples from
each disability group, compared to uninjured controls. * Indicates up- or down-regulation determined by MAS v5.0.
doi:10.1371/journal.pone.0124755.g002
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inflammatory changes along the neuraxis leading to sensory hypersensitivity [25, 27]. It trig-
gers a loss of predominantly myelinated nerve fibres distal to the ligation and Wallerian degen-
eration, sensitisation to chemical and inflammatory mediators, altered phenotypes of surviving
fibres, sprouting of sympathetic fibres and ectopic firing [66]. These changes are initially adap-
tive, promoting injury healing by signalling acute nociception and through immune-mediated
repair and removal of cellular debris. However if these processes persist they can lead to central
sensitisation, where neurons in the spinal cord dorsal horn change their phenotype, through al-
tered gene expression, leading to nociceptive signalling in the absence of tissue damage. Many
of these mal-adaptive changes underlie the characteristic changes in sensation associated with
sensory-discriminative aspects of neuropathic pain, such as allodynia, hyperalgesia, and spon-
taneous pain, and changes in expression of several ‘pain genes’ have been associated with these.
The changes in gene expression identified in all animals following CCI, likely play a role in
Fig 3. Gene transcripts, which encode for proteins involved in inflammation and/or cellular stress, that are specifically regulated in the lumbar
spinal cord after CCI, as determined by microarray analysis. Changes in gene expression have been tested at both 2 and 6 days after CCI on pooled
mRNA samples from each disability group, compared to uninjured controls. * Indicates up- or down-regulation determined by MAS v5.0.
doi:10.1371/journal.pone.0124755.g003
Fig 4. Gene transcripts, which encode for proteins involved in cellular signalling, that are specifically regulated in the lumbar spinal cord after CCI,
as determined bymicroarray analysis.Changes in gene expression have been tested at both 2 and 6 days after CCI on pooled mRNA samples from each
disability group. * Indicates up- or down-regulation determined by MAS v5.0.
doi:10.1371/journal.pone.0124755.g004
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these sensory-discriminative abnormalities, which are seen in all disability groups after CCI
[25, 27]. Of the 26 ‘injury-dependent’ genes identified, at least 18 have a known role in nocicep-
tion or the development and/or maintenance of sensory abnormalities after nerve injury. Al-
though we cannot rule out that some of the changes in expression of these 26 genes may
represent the response to resident-intruder testing, this seems unlikely given that such a large
proportion of these genes have already been implicated in sensory abnormalities. Below we dis-
cuss these ‘injury-dependent’ genes.
Genes identified in both microarray and RT-PCR. Substantial changes in spinal cord
genes involved in neurotransmission were hypothesised given their importance in the mecha-
nisms of central sensitisation and its contribution to sensory abnormalities, which characterise
pain following nerve damage. The changes identified in this study included, the gene for the
GABAB receptor 1 (GABBR1) which was up-regulated, consistent with the findings of McCar-
son and colleagues [67], although down-regulation has been reported at later time-points [49,
68, 69]. A loss of GABAergic tone is reported in neuropathic pain states [70–72], and activation
of these receptors is antinociceptive [73, 74]. Thus, the up-regulation of spinal GABAR1 recep-
tor mRNA reported by us, and others [67] may reflect an initial compensatory response to the
loss of spinal cord GABA.
The up-regulation of the dopamine 3 (D3) receptor gene (DRD3) at day 6 following CCI
may also play a significant role in modulating spinal sensory mechanisms. A growing body of
literature supports a role for dopamine, and D2-like receptors (D2, D3 and D4), in the
Fig 5. Gene transcripts, which encode for proteins involved in cellular structure, that are specifically regulated in the lumbar spinal cord after CCI,
as determined bymicroarray analysis.Changes in gene expression have been tested at both 2 and 6 days after CCI on pooled mRNA samples from each
disability group, compared to uninjured controls. * Indicates up- or down-regulation determined by MAS v5.0.
doi:10.1371/journal.pone.0124755.g005
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descending inhibition of nociceptive signalling in the superficial layers of dorsal horn. D2-like
receptor agonists suppress nociceptive responses [75–78], therefore up-regulation of D3 may
reflect a compensatory response to injury-evoked over-activity of descending inhibitory
pathways.
A transient down-regulation of the expression of the opioid-like 1 receptor (OPRL1) identi-
fied at day 2 only, may contribute to the development of sensory abnormalities in the initial pe-
riod after injury. However expression patterns may well change at later time-points (see [69,
79]). The modulation of nociception by the OPRL1 is supported by observations from N/
OFQ-R-/- mice [80]; behavioural neuropharmacological studies [81–84]; and functional ana-
tomical observations [85]; however the precise roles for this receptor in the expression of sen-
sory changes following CCI remain to be systematically explored.
The COMT enzyme is a key modulator of dopaminergic and adrenergic neurotransmission
through its metabolic actions on catecholamines. In humans, the val158met polymorphic vari-
ant has a 3–4 fold lower activity [86], leading to increased pain sensitivity and affective ratings
of pain [87, 88], and is associated with several chronic pain conditions [89]. Systemic adminis-
tration of COMT inhibitors is pro-nociceptive, exacerbating pain in inflammatory pain models
via a β2/3-adrenergic mechanism; the dorsal horn of spinal cord, is one of several locations at
which this may occur [90, 91]. The superficial dorsal horn of the spinal cord has a high expres-
sion of COMT [92], and the decrease in COMTmRNA in all rats after CCI, may thus contrib-
ute to the maintenance of the sensory abnormalities, via locally increased catecholamines and
through β2/3-adrenergic receptors. In neuropathic conditions systemically administered
Fig 6. Gene transcripts, which encode for proteins involved in ionic balance, that are specifically regulated in the lumbar spinal cord after CCI, as
determined by microarray analysis. Changes in gene expression have been tested at both 2 and 6 days after CCI on pooled mRNA samples from each
disability group, compared to uninjured controls. * Indicates up- or down-regulation determined by MAS v5.0.
doi:10.1371/journal.pone.0124755.g006
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COMT inhibitors reduce pain hypersensitivity [93, 94]. However, our data suggest that this ef-
fect is unlikely to be mediated at the level of the spinal cord.
The glutamate-glutamine shuttle, which allows recycling of extrasynaptic glutamate, and is
catalysed by astrocytic glutamine synthetase (GLUL), has been implicated in persistent pain
[95, 96]. Moreover, GLUL inhibition has been shown to reduce nocifensive behaviour in a
model of inflammatory pain [97]. Our microarray and PCR findings, that GLUL expression, is
up-regulated following nerve injury in all rats, is in keeping with previous reports of increased
expression in the hypoglossal nucleus following hypoglossal nerve transection [98]. In this
study the authors hypothesised that this may be protective against the excitotoxic effects of the
excess of glutamate released following injury. Hence, the increase in glutamine synthetase may
be in response to excess glutamate release into the dorsal horn after CCI, more generally
changes in glutamate and GABA synthesis appears to promote central sensitisation, contribut-
ing to sensory abnormalities [95–97].
Our findings that peripheral benzodiazepine receptor (BZRP) expression is up-regulated in
all rats, 2 and 6 days after CCI is consistent with previous findings, where expression in the spi-
nal cord peaked at day 3 [46]. Further the sensory abnormalities evoked by nerve injury were
reversed by treatment with a BZRP antagonist and were associated with similar increases in
BZRP expression. The reversal of the sensory abnormalities, depended on inhibition of produc-
tion of the steroids, allopregnanolone and 3α,21-dihydroxy-5α-pregnan-20-one (3α,5α-
THDOC), positive allosteric modulators and activators of the GABAA receptor [99]. The
BZRP enhances the activity of the mitochondrial permeability transition pore (MPTP), and is
involved in steroid production, cell survival and inflammatory processes [100, 101]. BZRP is
also expressed by microglia, and has been reported to be significantly up-regulated in response
to neuroinflammation [102]. BZRP is involved in the induction of apoptosis following
Fig 7. Gene transcripts, which encode for proteins involved in transcriptional or translational processes, that are specifically regulated in the
lumbar spinal cord after CCI, as determined by microarray analysis.Changes in gene expression have been tested at both 2 and 6 days after CCI on
pooled mRNA samples from each disability group, compared to uninjured controls. * Indicates up- or down-regulation determined by MAS v5.0.
doi:10.1371/journal.pone.0124755.g007
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Fig 8. Gene transcripts that are significantly regulated in the lumbar spinal cord after CCI, as determined by real time PCR.Changes in gene
expression have been tested at both 2 and 6 days after CCI on pooled mRNA samples from each disability group, compared to uninjured controls. Genes
encoding; (A) receptors; (B) neurotransmitter degradation enzymes; and (C) neuropeptides. Statistically significant changes indicated by; * P<0.05 and
**P<0.005 (Pairwise Fixed Reallocation Randomisation Contest).
doi:10.1371/journal.pone.0124755.g008
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exposure to cytokines, such as TNF [100], an environment consistent with the dorsal horn of
the spinal cord after nerve injury.
Given that neuropathic pain due to nerve injury is now considered a neuro-immune disor-
der [103], it is no surprise that many genes involved in inflammation are up-regulated in the
dorsal horn of the spinal cord following nerve injury. The mechanism of action of these inflam-
matory mediators is generally to increase glial cell activation, as well as to increase firing rates
of neurons either directly or to sensitise them to other neurotransmitters.
Interleukin-6 (IL-6) is a major pro-inflammatory cytokine, expressed by neurons, microglia
and astrocytes [103]. Nerve injury has previously been shown to increase up-regulation of IL-6
at multiple sites along the neuraxis, particularly the dorsal horn of the spinal cord [104, 105].
Evidence for long term up-regulation of the IL-6 receptor mRNA in the spinal cord has also
been reported after CCI [106]. Although IL-6 and its receptor play a critical role in nerve regen-
eration [107, 108], they are also central to the development and maintenance of sensory abnor-
malities [104, 109–112]. Thus, the increase in IL-6R mRNA reported here, in all rats post-CCI
is likely to potentiate nociceptive signalling.
Genes identified using the microarrays. A range of inflammatory-related genes were un-
covered in the microarrays, but were not subjected to confirmation using real time PCR. The
significant congruence of these data with that reported in a number of earlier published reports
as well as a recent meta-analysis confirms the likely importance of our findings.
A massive (57-fold) up-regulation of spinal cord expression of the chemokine CCL2
following CCI has previously been reported on day 14 after CCI, as well as in four independent
microarray studies [49], confirming the robust comparability of our data with the existing liter-
ature. We identified a 9-fold increase in CCL2 mRNA in the dorsal horn of the spinal cord in
all CCI rats by day 6, the largest increase in any gene on our microarray. CCL2 has been impli-
cated in sensory abnormalities following nerve injury through recruitment and activation of
microglia and direct excitation of spinal cord neurons [113–116].
Increased expression of glial fibrillary acidic protein (GFAP) following nerve injury has
been documented in six independent microarray studies in models of neuropathic pain, as well
as real time RT-PCR after CCI [49], the significant up-regulation seen in all our nerve injured
rats fits well with these data. GFAP is a well-characterised structural protein associated with as-
trocyte activation. In general central activation of astrocytes is associated with development
and maintenance of sensory abnormalities, through the production and release of inflammato-
ry mediators [103]. Furthermore, the increases in the pro-inflammatory cytokine, IL-18, and
macrophage migration inhibitory factor (MIF) reported here have also previously been shown
to increase their spinal cord expression following nerve injury, and have been implicated in
contributing to sensory abnormalities [117–120].
These examples of comparable findings across studies adds confidence to the significance
and importance of the disability-specific genes defined in the microarray and RT-PCR analy-
ses, which are now considered.
Disability-specific gene changes
Changes in affective-motivational state are an integral aspect of the pain experience, manifesting
in behavioural disturbances described as disabilities in many neuropathic pain sufferers. Changes
in gene expression at multiple levels of the neuraxis, including the first synapse are likely to un-
derpin the onset of such problems. In rats, sciatic nerve CCI triggers distinct patterns of beha-
vioural change, which may be driven in part by altered regulation of gene expression in L4-L6
spinal cord structures (neurons, glial cells, vasculature), which selectively influences spinal neu-
rons with supra-spinal targets. Overall, we have identified 54 ‘disability-specific’ genes, which are
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either uniquely regulated in rats with Pain & Disability, or in rats without persistent disability
(Pain alone / Pain & Transient Disability), compared to uninjured controls. Each gene showed a
unique temporal and dynamic pattern of regulation in the spinal cords of rats from each disabili-
ty sub-population. These differential patterns of gene expression may be central to the develop-
ment of complex behavioural changes, such as reduced dominance in social interactions,
disrupted sleep-wake cycles, and disrupted HPA and HPT axes, seen in the Pain & Disability co-
hort [26, 27, 31, 32].
Whilst twenty-one of the 54 ‘disability-specific’ genes have previously been suggested to
contribute to acute nociception or the sensory abnormalities following nerve-injury, a role for
these genes in the affective-motivational aspects of pain is a novel possibility suggested by our
data. Indeed, to our knowledge no studies outside our laboratory have attempted to compare
gene expression changes in sub-populations of rats displaying markedly different behavioural
responses following nerve injury. Below we discuss these ‘disability-specific’ genes in the con-
text of the function of their protein product.
Genes identified in both microarray and RT-PCR. Neurotransmitter genes: Several
genes involved in glutamate neurotransmission were uniquely regulated in rats with disrupted
social interactions (i.e., disability). The AMPA receptor 2 subunit (GRIA2), is reported to be
downregulated in the L4-L6 spinal cord 24 hours after hindpaw inflammation and after 2 days
in the ventral horn following sciatic nerve crush [121, 122]. After CCI there are increased pro-
tein levels for AMPA receptor subunits in the dorsal horn at 4 and 8 days after CCI [123]. Our
data showed a select reduction of GRIA2, mRNA expression 2 days after injury in rats with
Pain & Disability, which returns by day 6.
The NMDA receptor consists of heterotetrameric assemblies comprised most commonly of
two NR1 (GRIN1) subunits, and two NR2A-D (GRIN2A-D,) subunits. Following CCI, NR1
and NR2 mRNA expression has been reported to increase in the dorsal horn ipsilateral to the
injury from day 3 post-injury up to day 14 [124]. Although the specific NR2 subunit was not
specified, interrogation of the primer sequences indicated it was the GRIN2A gene (NR2A)
that was measured. Twenty-one days after spinal nerve ligation (SNL) dorsal horn expression
of the NR2D subunit (mRNA and protein) was no different to that of uninjured rats [125]. In
the ventral horn, sciatic nerve transection leads to a decrease in NR1, NR2B and NR2D
mRNAs and NR1 protein [126], highlighting a possible role for axotomy in triggering these
ventral horn changes in gene regulation. We are not aware of any studies to date that have in-
vestigated the regulation of the NR2C mRNA in response to peripheral nerve injury. Our data
showed decreased NR1 (GRIN1), NR2C (GRIN2C) and NR2D (GRIN2D) mRNA in the L4-L6
spinal cord of rats with Pain & Disability six days after CCI. Whether these changes in mRNA
are translated into protein/s is the next step in determining the functional significance of these
gene expression data. For example, it would be critical to define how a reduction in expression
of NR1 and NR2C/D subunits in Pain & Disability rats might affect glutamatergic receptor
transmission in L4-L6 spinal segments. NMDA receptors with NR2A/B subunits are more sen-
sitive to Mg2+ block and have a more rapid EPSC decay, than receptors containing NR2C/D
subunits [127, 128]. Thus, NR2A/B containing receptors deactivate faster than those with
NR2C/D subunits. The expression of NR2C/D subunits is restricted to inhibitory interneurons
in the superficial dorsal horn, unlike NR2A/B which appear ubiquitous [129]. It is clear that
several AMPA and NMDA receptor subunit genes have ‘disability-specific’ spinal cord expres-
sion after CCI. These receptor expression patterns likely cause alterations in glutamatergic sig-
nalling, which ultimately promotes activity in ascending pathways, which drive the expression
of behavioural disabilities.
The cannabinoid receptor 1 (CNR1) is highly expressed by both neurons and glia in superfi-
cial dorsal horn of the spinal cord [130]. In experimental groups using small numbers of rats,
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protein levels for the CNR1 receptor in the lumbar dorsal horn are reported to increase after
CCI [131, 132]. Further, CNR1 mRNA has been reported to increase in other models of neuro-
pathic pain in several microarray studies [49, 131]. Here we confirm upregulation of spinal
CNR1 mRNA, but only in the spinal cord of Pain & Disability rats. Therefore CNR1 may have
an as yet undetermined role in the expression of disability. The increase in CNR1 mRNA in a
select subgroup of rats was unexpected since it is suggested to enhance anti-nociception, how-
ever we have previously reported that allodynia is equal across all disability rats [25, 27]. Fur-
thermore, an anti-nociceptive role is well established, with endogenous cannabinoids, as well
as exogenously applied cannabinoid agonists, consistently reported to attenuate hyperalgesia
and allodynia following nerve injury [131, 133–135].
Monoamine oxidase isoforms A (MAOA) and B (MAOB) metabolise noradrenaline and
dopamine as well as serotonin (5-HT) and are found in both neurons and glia. Lumbar spinal
MAOA levels increase following CCI, which can result in decreased spinal 5-HT concentra-
tions [136]. Decreased binding at spinal 5HT3 receptors has been suggested to both enhance
[137] and decrease [136, 138] nociception. However, monoamine oxidase inhibitors are anti-
nociceptive in models of neuropathic pain [136, 139] and analgesic in humans where they have
been prescribed for comorbid depression [140, 141]. Our microarrays revealed that at day 6
post-CCI, MAOAmRNA was increased in rats with Pain & Disability and MAOB mRNA was
increased in rats that did not develop disabilities at 2 days after injury (i.e., Pain alone). This is
the first report of complementary changes in spinal MAOA and MAOB mRNA expression in
behaviourally distinct subgroups of rats after CCI [136]. This temporally distinct and ‘disabili-
ty-specific’ pattern of MAO isoform expression may play a role in differentially shaping the ac-
tivity of ascending supraspinal pathways known to be involved in the affective-motivational
component of pain.
Genes identified using the microarrays. Inflammatory mediator genes: In addition to
genes identified in the neurotransmission group, large numbers of disability-specific genes reg-
ulated from the inflammation functional group were identified. Thus, the expression of disabil-
ity may be driven in part by a specific immune response. This suggestion is supported by the
agreement of findings from earlier studies and the present findings. For example, complement
component 3 (C3) is part of the innate immune system. C3 mRNA is upregulated after CCI,
and C3 contributes to development of sensory abnormalities [46, 49, 142]. We confirmed C3
mRNA upregulation in all rats by day 6, however there is an earlier up-regulation in Pain &
Disability rats, suggesting a more rapid complement activation in this subgroup.
Prostaglandin F (PTGRF) receptors are known to be involved in the development of ATP-
induced allodynia, and are co-localised with P2X2/3 (P2RX2) receptors in spinal cord neurons
[143]. Our data showed the PTGRF receptor gene was initially down-regulated at day 2 in Pain
& Disability rats, before both the PTGRF and P2RX2 genes were up-regulated again in only
Pain & Disability rats at day 6. P2X receptors play a role in allodynia and hyperalgesia follow-
ing nerve injury [144], whilst an antagonist of P2X2/3 receptor heterodimers reduced sensory
abnormalities after CCI [145].
Selective increases in C3, ciliary neurotrophic factor (CNTF) an IL-6-like cytokine and,
PTGRF and P2RX2 receptors, in the spinal cord of Pain & Disability rats may indicate an exag-
gerated and unique immune response in these rats, which if restricted to specific locations of
the spinal cord, has the potential to activate ascending pathways specific to the expression
of disability.
Cellular stress genes: There are also clusters of genes related to the response to cellular stress,
which are elevated specifically in Pain & Disability rats at day 6, suggesting an exaggerated re-
sponse to injury. These genes are indicative of the presence of oxidative and cellular stress and
include, superoxide dismutase 1 (SOD1) and 2 (SOD2), heme oxygenase (HO), heat shock
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10kDa protein (HSP10), apurinic/apyrimidinic endonuclease (APE1), proteasome subunit
alpha (PSMA3), metallothionein-1A (MT1A), calpain-1 (CAPN1) and the voltage-dependent
anion channel 1 (VDAC1).
Genes regulating cellular processes and homeostasis: Many genes in the cellular structure,
cellular signalling, ionic balance and transcription and translation functional groups are identi-
fied here to play a role in the expression of disability. For example, mRNA expression levels of
the intermediate filament protein, vimentin (VIM), in the lumbar spinal cord are up-regulated
at day 2 in rats without persistent disability but then return to normal by day 6, whilst in Pain
& Disability rats there is a delayed but persistent increase. We have previously shown that
VIM, is increased in the midbrain periaqueductal gray of Pain & Disability rats [29], indicative
of astrocyte proliferation [146]. Hence, a similar pattern of VIM expression occurs at both the
spinal and supraspinal levels and is associated with the expression of disability in both cases.
The nestin gene (NES) encodes an intermediate filament protein found in both neuronal and
glial precursors, and its expression increases in the spinal cord after nerve injury [147]. Here,
the mRNA expression pattern of NES, mirrors that of VIM in rats without persistent disability,
suggesting cellular proliferation may occur at early stages after CCI in these rats, but normalises
by day 6. Therefore, we hypothesise early and transient changes in intermediate filaments NES
and VIM in rats without persistent disability aid recovery, but ongoing changes in VIM in Pain
& Disability rats contributes to the expression of disability, perhaps through an over exaggerat-
ed astrocyte proliferation.
Summary
We have shown that the overall ‘signatures’ of gene regulation changes are different between
rats with or without disability. That is, there are more ‘disability-specific’ genes with altered
regulation in Pain & Disability rats (n = 35), compared to rats without ongoing disability (Pain
alone and Pain & Transient Disability) (n = 12). Of the thirty-five genes regulated in Pain &
Disability rats, approximately two-thirds (65%) were genes in the neurotransmission and in-
flammatory and/or cellular stress subgroups (compared to only 34% in rats without disability).
Forty percent of the genes regulated in rats without disability (Pain alone and Pain & Transient
Disability) were genes regulating cellular processes and homeostasis (compared to only 6% in
Pain & Disability rats).
The genes regulated uniquely in rats without persistent disability encode for genes regulat-
ing cellular processes and homeostasis, which we suggest contribute to resilience and accelerat-
ed recovery from the injury-related triggers of behavioural change. In contrast, select patterns
of activation of the neuro-inflammatory repertoire in Pain & Disability rats may lead to dra-
matic alterations in ascending supra-spinal signals.
This view is supported by our earlier experiments, which showed enhanced astrocyte activa-
tion and evidence of cell death in lumbar spinal recipient columns of the PAG of Pain & Dis-
ability rats [28, 29]. It is therefore tempting to suggest these similar midbrain regions receive
specific spinal outputs that are regulated selectively by the gene expression changes we have
identified in this subgroup of disabled rats.
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